Business
Zynerba Failure Highlights the Need for Expertise, Broader Portfolios -- SECFilings.com
Zynerba Failure Highlights the Need for Expertise, Broader Portfolios -- SECFilings.com.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n \n \n Zynerba Failure Highlights the Need for Expertise, Broader Portfolios -- SECFilings.com\n \n \nZynerba Failure Highlights the Need for Expertise, Broader Portfolios -- SECFilings.com\n \n REDONDO BEACH, CA--(Marketwired - Aug 15, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc.'s. (OTCQB: AXIM) clinical progress and broad portfolio in light of Zynerba's recent Phase II cannabidiol (CBD) gel patch failure.\n The clinical study of 188 adults with refractory epilepsy found that those taking a low dose of ZYN002 experienced an 18.4% median reduction in seizures compared to a 14.0% reduction for high dosages and an 8.7% reduction for placebo. The endpoint missed and the lack of a dose-dependent response suggest that the underlying delivery system was ineffective. The therapeutic also failed to beat placebo in any of the secondary goals.\n Learning from Failure\n Zynerba's clinical trial failure underscores several key points that cannabis investors may want to carefully consider when choosing their next investments.\n First, investors should exercise caution when investing in companies with small clinical pipelines. Zynerba's only other clinical program is ZYN001, which is a THC prodrug patch that has yet to clear Phase I clinical trials, which means that the failure of ZYN002 in Phase II clinical trials took a significant toll on the stock price. Investors should seek out companies with broad portfolios where a single failure won't jeopardize the entire company.\n Second, working with cannabinoids may be more difficult than many companies and researchers had initially thought. Cannabinoids have complex interactions with the human body and don't always behave as researchers would expect. Investors should look for companies that have deep expertise in medicine, as well as positive signs of efficacy in earlier Phase I and pre-clinical trials to maximize their odds of success.\n Third, it may be tempting to assume that cannabinoids have been over-hyped following Zynerba's failure, but investors shouldn't give up on the space. Zynerba's clinical trial did show that CBD is safe and well-tolerated, while GW Pharmaceuticals plc's clinical programs have confirmed that both THC ...